The evaluation of dupilumab treatment response in atopic dermatitis patients
Yıl: 2021 Cilt: 8 Sayı: 2 Sayfa Aralığı: 145 - 149 Metin Dili: İngilizce DOI: 10.14744/nci.2020.42375 İndeks Tarihi: 09-05-2021
The evaluation of dupilumab treatment response in atopic dermatitis patients
Öz: OBJECTIVE: This study aims to demonstrate real-life effectiveness of dupilumab treatment in moderate-to-severe atopic dermatitis patients.METHODS: The 14 patients diagnosed with moderate-to-severe atopic dermatitis were included in this study. All of the patients started dupilumab treatment in our faculty between October 2019 and October 2020. The patients were evaluated at the beginning of the treatment and after 12 weeks of treatments. The baseline scoring atopic dermatitis (SCORAD) scores, the total immunoglobulin E (IgE) levels, and the visual analog scale (VAS) of 0–10 points for itch intensity compared with the post-treatment scores.RESULTS: The SCORAD scores, the serum total IgE levels, and the VAS itch scores of the patients receiving dupilumab treatment dropped significantly following 12 weeks of dupilumab treatment. No significant correlation was demonstrated between the initial SCORAD scores and the serum total IgE values. Besides, no correlation was shown to exist in the reduction of the SCORAD and the serum total IgE values after dupilumab treatment.CONCLUSION: Dupilumab treatment showed significant improvement in disease severity with remarkable reduction in serum total IgE levels.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol 2017;77:274–9.e3
- 2. Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology 2017;233:344–57.
- 3. van der Schaft J, Politiek K, van den Reek JMPA, Christoffers WA, Kievit W, de Jong EMGJ, et al. Drug survival for ciclosporin A in a longterm daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 2015;172:1621–7.
- 4. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130–9.
- 5. Frampton JE, Blair HA. Dupilumab: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2018;19:617–24.
- 6. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology 1993;186:23–31.
- 7. Laurent J, Noirot C, Ansquer JC, Laurent G, Kestenbaum S, Lagrue G. How to define the normal level of serum IgE in adults? [Article in French]. Ann Med Interne (Paris) 1985;136:419–22.
- 8. Olesen CM, Holm JG, Nørreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 2019;33:1562–8.
- 9. Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al; Dupilumab Italian National Access Program (Dup-INAP group). Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2019:1–7.
- 10. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335–48.
- 11. Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al; Groupe de Recherche sur l’Eczéma aTopique (GREAT), France. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019;81143–51.
- 12. Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, Ruiz-Villaverde R, Valero A, Izu-Belloso R, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol 2019;181:1072–4.
- 13. Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol 2017;140:1708–10.e1
| APA | Askin O, Yucesoy S, Serdaroğlu S (2021). The evaluation of dupilumab treatment response in atopic dermatitis patients. , 145 - 149. 10.14744/nci.2020.42375 |
| Chicago | Askin Ozge,Yucesoy Sera Nur,Serdaroğlu Server The evaluation of dupilumab treatment response in atopic dermatitis patients. (2021): 145 - 149. 10.14744/nci.2020.42375 |
| MLA | Askin Ozge,Yucesoy Sera Nur,Serdaroğlu Server The evaluation of dupilumab treatment response in atopic dermatitis patients. , 2021, ss.145 - 149. 10.14744/nci.2020.42375 |
| AMA | Askin O,Yucesoy S,Serdaroğlu S The evaluation of dupilumab treatment response in atopic dermatitis patients. . 2021; 145 - 149. 10.14744/nci.2020.42375 |
| Vancouver | Askin O,Yucesoy S,Serdaroğlu S The evaluation of dupilumab treatment response in atopic dermatitis patients. . 2021; 145 - 149. 10.14744/nci.2020.42375 |
| IEEE | Askin O,Yucesoy S,Serdaroğlu S "The evaluation of dupilumab treatment response in atopic dermatitis patients." , ss.145 - 149, 2021. 10.14744/nci.2020.42375 |
| ISNAD | Askin, Ozge vd. "The evaluation of dupilumab treatment response in atopic dermatitis patients". (2021), 145-149. https://doi.org/10.14744/nci.2020.42375 |
| APA | Askin O, Yucesoy S, Serdaroğlu S (2021). The evaluation of dupilumab treatment response in atopic dermatitis patients. İstanbul Kuzey Klinikleri, 8(2), 145 - 149. 10.14744/nci.2020.42375 |
| Chicago | Askin Ozge,Yucesoy Sera Nur,Serdaroğlu Server The evaluation of dupilumab treatment response in atopic dermatitis patients. İstanbul Kuzey Klinikleri 8, no.2 (2021): 145 - 149. 10.14744/nci.2020.42375 |
| MLA | Askin Ozge,Yucesoy Sera Nur,Serdaroğlu Server The evaluation of dupilumab treatment response in atopic dermatitis patients. İstanbul Kuzey Klinikleri, vol.8, no.2, 2021, ss.145 - 149. 10.14744/nci.2020.42375 |
| AMA | Askin O,Yucesoy S,Serdaroğlu S The evaluation of dupilumab treatment response in atopic dermatitis patients. İstanbul Kuzey Klinikleri. 2021; 8(2): 145 - 149. 10.14744/nci.2020.42375 |
| Vancouver | Askin O,Yucesoy S,Serdaroğlu S The evaluation of dupilumab treatment response in atopic dermatitis patients. İstanbul Kuzey Klinikleri. 2021; 8(2): 145 - 149. 10.14744/nci.2020.42375 |
| IEEE | Askin O,Yucesoy S,Serdaroğlu S "The evaluation of dupilumab treatment response in atopic dermatitis patients." İstanbul Kuzey Klinikleri, 8, ss.145 - 149, 2021. 10.14744/nci.2020.42375 |
| ISNAD | Askin, Ozge vd. "The evaluation of dupilumab treatment response in atopic dermatitis patients". İstanbul Kuzey Klinikleri 8/2 (2021), 145-149. https://doi.org/10.14744/nci.2020.42375 |
